21:35 , Jan 11, 2019 |  BioCentury  |  Emerging Company Profile

Artios: Probing DNA Damage

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to...
19:39 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Ribon raises $65M series B to target monoPARPs

A $65 million series B round will help Ribon Therapeutics Inc. (Lexington, Mass.) move its lead small molecule PARP-7 inhibitor into the clinic this year for squamous cell carcinoma of the lung. New investor Novartis...
12:01 , Jan 4, 2019 |  BC Extra  |  Financial News

Ribon raises $65 million series B to target monoPARPs

A $65 million series B round will help Ribon Therapeutics Inc. (Lexington, Mass.) move its lead small molecule PARP-7 inhibitor into the clinic this year for squamous cell carcinoma of the lung. New investor Novartis...
18:29 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Neurodegeneration play Rheostat raises $23M series A

Rheostat Therapeutics (Cambridge, Mass.) raised $23 million in a series A round to bring its first programs in neurodegenerative disease to IND. The round was co-led by MRL Ventures Fund and AbbVie Ventures, with participation...
00:06 , Nov 27, 2018 |  BC Extra  |  Financial News

Neurodegeneration play Rheostat raises $23M series A

Rheostat Therapeutics (Cambridge, Mass.) raised $23 million in a series A round to bring its first programs in neurodegenerative disease to IND. The round was co-led by MRL Ventures Fund and AbbVie Ventures, with participation...
15:56 , Nov 16, 2018 |  BC Week In Review  |  Financial News

M Ventures leads $30M series A for RNA start-up Ribometrix

RNA company Ribometrix Inc. (Durham, N.C.) raised $30 million in a series A round led by M Ventures on Nov. 13. Fellow new investors Amgen Ventures, Pappas Capital and Illumina Ventures also participated, as did...
11:35 , Nov 13, 2018 |  BC Extra  |  Financial News

M Ventures leads $30M series A for RNA start-up Ribometrix

RNA company Ribometrix Inc. (Durham, N.C.) raised $30 million in a series A round led by M Ventures. Fellow new investors Amgen Ventures, Pappas Capital and Illumina Ventures also participated, as did existing investors SV...
11:33 , Nov 13, 2018 |  BioCentury  |  Finance

Playing in RNA

M Ventures, the strategic venture arm of Merck KGaA (Xetra:MRK), is adding another RNA company to its portfolio by leading a $30 million series A round for Ribometrix Inc. Fellow new investors Amgen Ventures, Pappas...
00:36 , Nov 7, 2018 |  BC Extra  |  Company News

Management tracks: Five Prime, Alder

Five Prime Therapeutics Inc. (NASDAQ:FPRX) hired David Smith as EVP and CFO, effective Nov. 26. He will replace Linda Rubinstein, who was interim CFO of the cancer company. Smith was COO of IntegenX Inc. until...
18:37 , Oct 19, 2018 |  BC Week In Review  |  Company News

AbbVie, Morphic partner on antifibrotic integrins

AbbVie Inc. (NYSE:ABBV) agreed to pay Morphic Therapeutic (Waltham, Mass.) $100 million up front for exclusive options to license antifibrotic integrins to block transforming growth factor β (TGFβ) activation via multiple undisclosed targets. Morphic is...